CN Patent

CN114828852A — 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合

Assigned to F Hoffmann La Roche AG · Expires 2022-07-29 · 4y expired

What this patent protects

本发明涉及用于治疗乙型肝炎病毒感染的组合物和方法。特别地，本发明涉及一种组合疗法，其包括施用某些抗病毒化合物和免疫调节剂化合物。

USPTO Abstract

本发明涉及用于治疗乙型肝炎病毒感染的组合物和方法。特别地，本发明涉及一种组合疗法，其包括施用某些抗病毒化合物和免疫调节剂化合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN114828852A
Jurisdiction
CN
Classification
—
Expires
2022-07-29
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.